KYMR Q3 EPS Estimate Reduced by Brookline Capital Management

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Brookline Capital Management lowered their Q3 2025 earnings estimates for shares of Kymera Therapeutics in a report issued on Wednesday, June 25th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($1.03) per share for the quarter, down from their prior forecast of ($0.85). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($4.72) EPS, FY2027 earnings at ($5.20) EPS, FY2028 earnings at ($6.24) EPS and FY2029 earnings at ($5.61) EPS.

Several other research analysts have also issued reports on KYMR. Oppenheimer reduced their target price on shares of Kymera Therapeutics from $56.00 to $53.00 and set an "outperform" rating on the stock in a research note on Friday. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Jefferies Financial Group set a $64.00 target price on shares of Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price on the stock in a research note on Monday, June 2nd. Finally, Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $59.61.

Kymera Therapeutics Trading Down 3.5%

Shares of NASDAQ KYMR opened at $44.12 on Monday. The firm has a market capitalization of $2.87 billion, a PE ratio of -14.23 and a beta of 2.07. Kymera Therapeutics has a 1 year low of $19.45 and a 1 year high of $53.27. The firm's 50-day moving average is $37.08 and its 200-day moving average is $35.76.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The company's revenue was up 114.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.69) EPS.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Elena Ridloff sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total transaction of $553,200.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,349 shares of company stock worth $2,334,301. Company insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp raised its holdings in shares of Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after purchasing an additional 53,658 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $344,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after purchasing an additional 20,346 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after purchasing an additional 6,509 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after purchasing an additional 77,912 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.